Transgender hormone therapy (THT) is a medically supervised treatment that uses sex steroid hormones to align secondary sex characteristics with a person’s affirmed gender identity. Clinically, it is most often considered for persistent gender dysphoria or gender incongruence, a condition characterized by distress or impairment related to incongruence between experienced/expressed gender and assigned sex at birth. The core medical rationale is endocrine: targeted administration of testosterone, estrogen, and/or androgen blockers modulates hypothalamic-pituitary-gonadal signaling and alters developmental trajectories of traits such as body hair, fat distribution, breast development, muscle mass, and libido. In practice, the decision to start THT follows a structured assessment of gender-related goals, mental and physical health, capacity to consent, and assessment of contraindications.
Assessment typically includes a comprehensive medical history (cardiovascular risk, thromboembolic history, migraine with aura, smoking, liver disease, clotting disorders, substance use, and medication review), a mental health evaluation focusing on dysphoria severity and comorbidities (depression, anxiety disorders, autism spectrum conditions, trauma-related symptoms), and baseline laboratory work. Common baseline tests include complete blood count, metabolic panel, liver enzymes, lipid profile, HbA1c or fasting glucose, prolactin when relevant, and pregnancy status when indicated. Hormone levels (e.g., estradiol, testosterone) are measured to guide dosing and monitor suppression or achievement targets. Some frameworks also recommend screening for sexually transmitted infections and discussion of reproductive options, since THT can reduce fertility; fertility preservation should be offered early when desired.
For transfeminine care, estrogen is typically the primary hormone. Forms include oral estradiol, transdermal estradiol patches or gels, and in some settings injectable formulations. Estrogen induces breast tissue development through estrogen receptor signaling in mammary tissue, reduces androgen effects, and promotes characteristic fat redistribution toward a more typically feminine pattern. Choice of route matters for safety. Transdermal estrogen is frequently favored in individuals with elevated risk of venous thromboembolism because it avoids first-pass hepatic metabolism that increases certain coagulation factors. For masculinizing care, testosterone is administered via injections, transdermal preparations, or gels. Testosterone increases muscle mass and strength, deepens voice via laryngeal growth, increases facial and body hair via androgenic follicles, and alters fat distribution. Both feminizing and masculinizing regimens often include adjunctive agents.
Androgen blockade is commonly used in transfeminine therapy to reduce testosterone and mitigate virilizing androgen effects. Agents may include GnRH analogs or androgen receptor blockers such as spironolactone in some clinical settings. GnRH analogs suppress gonadotropin secretion at the pituitary level, leading to decreased testicular androgen production. Androgen receptor blockers reduce androgen action at target tissues. Safety monitoring for androgen blockade focuses on electrolytes and renal function (for spironolactone), blood pressure, and hormone response. Gonadotropin suppression may also require monitoring for bone density considerations over time.
Major safety domains include cardiovascular and thromboembolic risk, metabolic effects, liver effects, bone health, and potential impacts on mood. Estrogen therapy can alter coagulation parameters, lipid profiles, and blood pressure patterns; therefore, clinician-guided risk stratification is essential, particularly for smokers, individuals with personal or family history of thrombosis, and those with known thrombophilias. Testosterone therapy can increase hematocrit in some patients, potentially raising the risk of hyperviscosity; regular complete blood counts are recommended, with dose adjustments if hematocrit rises beyond safe thresholds. Both estrogen and testosterone can influence insulin sensitivity and body composition, so periodic metabolic monitoring is prudent.
Cancer screening considerations remain complex. THT does not eliminate the need for age-appropriate screening for breast, prostate, cervical, colorectal, and other cancers depending on anatomy and age. The decision to initiate or modify screening should consider anatomy, duration of hormone exposure, and guideline recommendations. Bone health requires attention: hypogonadism or inadequate hormone exposure can contribute to decreased bone mineral density, while appropriately dosed hormones generally support bone maintenance.
From a psychological perspective, alleviating gender dysphoria can improve quality of life, reducing distress, anxiety, and depressive symptoms for many patients. However, THT is not a standalone mental health intervention; comorbid mental health conditions require parallel care. Clinicians also monitor for mood changes and suicidality, especially in the context of minority stress, discrimination, and social determinants of health.
Overall, evidence-based practice emphasizes individualized dosing, shared decision-making, and longitudinal monitoring. Outcomes are typically assessed through physical changes over time (e.g., breast development over months to years in transfeminine care; voice and hair changes over months to years in masculinizing care), patient-reported satisfaction, functional outcomes, and adverse event surveillance. With careful screening and follow-up, THT can be delivered safely and effectively, aligning medical endocrine interventions with the patient’s affirmed gender identity and health goals. Source: @47buckets
47buckets: Darryn Peterson gets buckets in such a natural smooth way. The imbalance of negative and positive around his name is just dumb. He’s gonna transition seamlessly and be a star in this league.. #breaking
— @47buckets May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
